Mele et al. pointed out that the inhibitory effect of lapatinib on breast cancer cells may be elevated by blocking glucose-6-phosphate dehydrogenase (G6PD), the limiting enzyme of the pentose phosphate pathway, through disrupting autophagy. Here, G6PD is linked to breast cancer.